GLP-1 Generics Could Reshape Local Obesity Market

Original Article by Tanya Pampalone, Mia Malan and Anna-Maria van Niekerk | Bhekisisa Centre for Health Journalism | 24 August 2026

GLP-1 generics could cut obesity drug costs, challenge illegal sales and expand access as more semaglutide products seek approval.

Image | Haberdoedas | Unsplash/aLCcungJbrc

GLP-1 generics could cut obesity drug costs, challenge illegal sales and expand access as more semaglutide products seek approval.

Subscription Required

You must be a subscriber to access all of this content.

Already a subscriber? Log in here

Dr Thembisile Xulu is the new health Director-General, inheriting a strained department, healthcare-worker shortages and NHI litigation.

Gauteng is losing 100 nurses a month and needs R5.7bn to fill a 16,000-post gap. This shortage now flagged as a key risk to the NHI rollout.

Regulation, not demand, blocks affordable cover: medical schemes should be allowed to offer low-cost benefit options (LCBOs) now.